. Author manuscript; available in PMC: 2021 Jun 1.

Published in final edited form as: Cancer Epidemiol Biomarkers Prev. 2020 Oct 22;29(12):2486–2494. doi: 10.1158/1055-9965.EPI-20-0223

Table 2:

Candidate BE risk stratification markers

Biomarker	Study Design	Sample Size	Outcome
Abnormal DNA ploidy, 9pLOH, 17pLOH³⁴	Prospective Cohort	N=243	RR=38.7
			(95% CI 10.8–138.5)

Aneuploidy, tetraploidy⁶⁰	Retrospective analysis	N=322	RR=11 (95% CI 5.5–21)

LOH by FISH: 17p13.1⁶¹	Retrospective analysis of surveillance cohort	N=151	5% of NDBE
			9% of LGD
			46% of HGD

CNA and LOH by FISH:	Prospective	N=138	LGD: sens 70%, spec 89%
8q24, 9p21, 17q11.2, and 20q13.2⁶²			HGD: sens 84%, spec 93%
			EAC: sens 94%, spec 93%

Hypermethylation of CDKN2A, RUNX3, HPP1⁶³	Retrospective and longitudinal	N=53	CDKN2A OR 1.74
			RUNX3 OR 1.8
			HPP1 OR 1.77

Jin methylated gene panel⁶⁴	Retrospective, multi-center, double-blinded	N=50 progressors	AUC=0.843 at 2 years
		N=145 non-progressors	AUC=0.829 at 4 years

Tissue Cypher⁵⁹	Case-Control multi-center	N=145 non-processors, N=45 progressors	OR 9.4 High vs. Low risk (95% CI 2.65, 33.28) OR 2.35 Intermediate vs. Low risk (95% CI 0.66, 8.41)